Display options
Cite
van Golen, K. L., Bao, L., DiVito, M. M., Wu, Z., Prendergast, G. C., & Merajver, S. D. (2002). Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor 1 Supported by National Cancer Institute Grant R01 CA 77612 (to SDM); Grant DAMD 17-00-1-0345, from The Department of Defense, United States Army Breast Cancer Program (to SDM); and Grant 5T32 CA 09537 (to SDM) and a postdoctoral fellowship (to KL v. G.) from the Susan G. Komen Breast Cancer Foundation. 1. Molecular cancer therapeutics, 1(8), 575-583.
van Golen, Kenneth L., et al. "Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor 1 Supported by National Cancer Institute Grant R01 CA 77612 (to SDM); Grant DAMD 17-00-1-0345, from The Department of Defense, United States Army Breast Cancer Program (to SDM); and Grant 5T32 CA 09537 (to SDM) and a postdoctoral fellowship (to KL v. G.) from the Susan G. Komen Breast Cancer Foundation. 1." Molecular cancer therapeutics 1.8 (2002): 575-583.
Copy Download .nbib Format: MLA
Share it on
Full text links
View full text

KL van Golen, LW Bao, MM DiVito, ZF Wu… - Molecular cancer …, 2002 - AACR

… 0345, from The Department of Defense, United States Army Breast Cancer Program (to SDM); and Grant 5T32 CA 09537 (to SDM) and a postdoctoral fellowship (to KL ….

postdoctoral

[No authors listed]

GSID: oKVaPWB7sZgJ

Excerpt

Inflammatory breast carcinoma (IBC) is a highly aggressive form of locally advanced breast cancer that has the ability to invade and block the dermal lymphatics of the skin overlying the …

Similar articles

Cited by